ArticleBMC research notes2025
Analysis of inflammation parameter value lymphocyte monocyte ratio (LMR), platelet lymphocyte ratio (PLR), and systemic inflammation response index (SIRI) to differentiate malignant and benign ovarian tumors.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy.Cancers · 2026Review
- Evaluation of systemic inflammation- and nutrition-based indices in the prediction of HPV persistence.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOvarian cancer is the leading cause of death from gynecological cancers. In the early stages, it is generally asymptomatic, leading to delays in the early diagnosis of ovarian cancer. Inflammation, which is the body's response to tissue damage, plays a crucial role in the pathogenesis of cancer. Inflammatory responses result in cellular changes, damaged tissue repair, and affected area proliferation. This research aims to determine the differences in LMR (Lymphocyte-to-Monocyte Ratio), PLR (Platelet-to-Lymphocyte Ratio), and SIRI (Systemic Immune-Inflammation Index), which were the parameters of inflammation between ovarian malignant tumors and benign ovarian tumors.
resultsThis retrospective cohort study analyzed medical records of 327 patients treated at Dr. Hasan Sadikin General Hospital, Bandung, between 2020 and 2022, including 166 cases of malignant ovarian tumors and 161 benign ovarian tumors. Inflammatory markers were calculated from routine blood counts. The mean LMR was significantly lower in the malignant group than the benign group (3.32 vs. 3.83, P = 0.004). Conversely, PLR and SIRI values were significantly higher in malignant tumors (PLR: 355 vs. 213, P = 0.001; SIRI: 3.50 vs. 2.97, P = 0.042). These findings suggest that LMR, PLR, and SIRI may serve as supportive inflammatory biomarkers in distinguishing malignant from benign ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.